Literature DB >> 29791832

Rationale, Opportunities, and Reality of Biosimilar Medications.

Gary H Lyman1, Robin Zon1, R Donald Harvey1, Richard L Schilsky1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29791832     DOI： 10.1056/NEJMhle1800125

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  20 in total

1.  Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.

Authors:  Quentin Riller; Camille Cotteret; Helga Junot; Neila Benameur; Julien Haroche; Alexis Mathian; Miguel Hie; Makoto Miyara; Patrick Tilleul; Zahir Amoura; Fleur Cohen Aubart
Journal:  J Neurol       Date:  2019-02-09       Impact factor: 4.849

Review 2.  Are Biosimilars the Future of Oncology and Haematology?

Authors:  Pier Luigi Zinzani; Martin Dreyling; William Gradishar; Marc Andre; Francisco J Esteva; Suliman Boulos; Eva González Barca; Giuseppe Curigliano
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

Review 3.  Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

Authors:  Ibrahim N Muhsen; Shahrukh K Hashmi; Dietger Niederwieser; Nicolaus Kroeger; Samir Agrawal; Marcelo C Pasquini; Yoshiko Atsuta; Karen K Ballen; Adriana Seber; Wael Saber; Mohamed A Kharfan-Dabaja; Walid Rasheed; Shinichiro Okamoto; Nandita Khera; William A Wood; Mickey B C Koh; Hildegard Greinix; Yoshihisa Kodera; Jeff Szer; Mary M Horowitz; Daniel Weisdorf; Mahmoud Aljurf
Journal:  Bone Marrow Transplant       Date:  2019-09-04       Impact factor: 5.483

4.  Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb.

Authors:  Jennifer Philippon Booth; Jeffrey Pilz
Journal:  Hosp Pharm       Date:  2021-09-16

5.  Naming Convention, Interchangeability, and Patient Interest in Biosimilars.

Authors:  Mariana P Socal; Jace B Garrett; William B Tayler; Ge Bai; Gerard F Anderson
Journal:  Diabetes Spectr       Date:  2020-08

6.  Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.

Authors:  Rieke Alten; Bogdan Batko; Tomas Hala; Hideto Kameda; Sebastiao C Radominski; Vira Tseluyko; Goran Babic; Carol Cronenberger; Sarah Hackley; Muhammad Rehman; Oliver von Richter; Min Zhang; Stanley Cohen
Journal:  RMD Open       Date:  2019-03-28

7.  Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment.

Authors:  Seung Kook Baek; Jae Hui Kim; Jong Woo Kim; Chul Gu Kim
Journal:  Sci Rep       Date:  2019-09-13       Impact factor: 4.379

8.  Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?

Authors:  Alexandros A Drosos; Eleftherios Pelechas; Paraskevi V Voulgari
Journal:  J Clin Med       Date:  2019-08-16       Impact factor: 4.241

9.  Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.

Authors:  Kiu Tay-Teo; André Ilbawi; Suzanne R Hill
Journal:  JAMA Netw Open       Date:  2019-01-04

10.  Academic oncology clinicians' understanding of biosimilars and information needed before prescribing.

Authors:  John W Cook; Megan K McGrath; Margie D Dixon; Jeffrey M Switchenko; R Donald Harvey; Rebecca D Pentz
Journal:  Ther Adv Med Oncol       Date:  2019-01-06       Impact factor: 8.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.